Ultragenyx Announces Completion of Phase 2 Study Enrollment for UX001 in Hereditary Inclusion Body Myopathy
30 oct. 2012 06h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 30, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced it...
Ultragenyx Announces Three Abstracts Accepted for Poster Presentation at 17th Annual World Muscle Society Congress
10 oct. 2012 16h30 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced...
Ultragenyx to Present at the 11th Annual BIO Investor Forum in San Francisco
03 oct. 2012 09h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Oct. 3, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company, today announced that Emil D. Kakkis, M.D., Ph.D, the company's CEO, will be presenting at the...
Ultragenyx to Present at the Stifel Nicolaus Weisel Healthcare Conference 2012 in Boston
30 août 2012 09h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 30, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company, today announced that Shalini Sharp, Chief Financial Officer, will be presenting at the Stifel...
Ultragenyx to Present at the Canaccord Genuity 32nd Annual Growth Conference on August 16, 2012
09 août 2012 09h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company, today announced that Emil D. Kakkis, MD, PhD, President and CEO, will be presenting at the...
Ultragenyx to Present at the 2012 Wedbush PacGrow Life Sciences Management Access Conference on August 15
07 août 2012 09h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company, today announced that Emil D. Kakkis, MD, PhD, President and CEO, will be presenting at the...
Ultragenyx Initiates Phase 2 Study of UX001 in Hereditary Inclusion Body Myopathy, a Rare Neuromuscular Disease
05 juil. 2012 09h00 HE
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 5, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced the...